Concepedia

Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

Christian Schindlbeck, Doris Mayr, Camille Olivier, Brigitte Rack, Verena Engelstaedter, J Jueckstock, C Jenderek, Ulrich Andergassen, Udo Jeschke, K Friese

Journal of Cancer Research and Clinical Oncology · 2010 · 34 citations · 21 references

DOIFull text

Open access

Concepts

References

21

Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer

Donald A. Berry, Kathleen A. Cronin, Sylvia K. Plevritis et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

, , +11

The HER‐2/ <i>neu</i> Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

Jeffrey S. Ross, Jonathan A. Fletcher · Stem Cells · 1998 · 1K citations · Full text

, , +15

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Mark N. Levine, V. Bramwell, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 1998 · 623 citations

, , +10

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2009 · 586 citations

, , +11

<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

Kathleen I. Pritchard, Lois E. Shepherd, Frances P. O’Malley et al. · New England Journal of Medicine · 2006 · 508 citations · Full text

, , +16